What is the main business of Xenira Pharmaceuticals?

The main business activity of Xenira Pharmaceuticals focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on March 28, 2024.

Where is the headquarters located?

The headquarters is located at: ul. Rakietowa 29A, 54-615 Wrocław.

Who is on the management board?

The management board consists of: Agnieszka Anna Teodoru (President of the Management Board) and Grzegorz Andrzej Kiełbowicz (Vice President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,750 (approx. $1,553).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

How much revenue was generated?

In 2025, the company generated total revenue of $26,671, representing an increase of 116.0% compared to 2024.

No, the company recorded a net loss of $60,078 in 2025. For comparison, in 2024 the loss was $71,926, meaning the company reduced its loss by 16.7%.

What is the main operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $45,739 in 2025, representing 64% of all operating expenses.

Xenira Pharmaceuticalssp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2024-03-28

Share capital

5 750,00 PLN

Activity description

Xenira Pharmaceuticals is a drug delivery technology company that specializes in lipid-based drug delivery systems to enhance the solubility, stability, and bioavailability of poorly water-soluble drugs and biopharmaceuticals. They offer a portfolio of customizable technologies, including nanostructured lipid carriers and solid lipid nanoparticles, aimed at developing value-added pharmaceutical products. Additionally, they provide flexible collaboration models, including technology transfer and in-house EU-GMP manufacturing.

Registered address

ul. Rakietowa 29A, 54-615 Wrocław, Poland

Website

xenirapharma.com

Electronic delivery address

AE:PL-23431-51031-TTHSB-21

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 26.67kMedianUSD 816.16kAverageUSD 29.28m

Net profit

This companyUSD -60.08kMedianUSD 8.96kAverageUSD 2.64m

Operating costs

This companyUSD 71.63kMedianUSD 701.47kAverageUSD 19.26m

Assets

This companyUSD 179.63kMedianUSD 800.13kAverageUSD 29.34m

Industry

Bank accounts

Registered as a VAT taxpayer on 2024-08-01. Active

PKO Bank Polski
19 1020 5242 0000 2302 0650 7414
PKO Bank Polski
24 1020 5242 0000 2102 0650 7422

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Agnieszka Anna Teodoru — President of the Management Board

Grzegorz Andrzej Kiełbowicz — Vice President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Agnieszka Anna Teodoru (48)	92	$1,242.57	80%
Others	23	$310.64	20%

The articles of association require board approval for share transfers.

Beneficial owners

Person	Rights
Filip Daniel Szachniewicz (22)	Shareholder of a limited liability company, 2500.0 PLN
Oliwier Daniel Szachniewicz (23)	Shareholder of a limited liability company, 2500.0 PLN

Competitors

	Name	Revenue	Website
	Pexon Polandsp. z o.o.	$122,615.96	pexon.pl
	Bioresearch PharmaS.A.	$21,432.15	bioresearchpharma.com

Change history

Date	Event
2026-03-13	Address change (Ul. Rakietowa 29a, 50-238, Wrocław → Ul. Rakietowa 29a, 54-615, Wrocław)
2026-03-13	Share capital change (5,000.00 PLN → 5,750.00 PLN)
2024-03-28	Entered in the register

FAQ

Last updated: 2026-07-17